Spots Global Cancer Trial Database for dhap
Every month we try and update this database with for dhap cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation | NCT00003143 | Lymphoma | Amifostine DHAP | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation | NCT00003143 | Lymphoma | Amifostine DHAP | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma | NCT00384553 | Non-Hodgkin's L... | Rituximab DHAP TEC autologous stem... | 18 Years - 65 Years | University of Magdeburg | |
| Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT01014208 | Lymphoma, Large... | OFATUMUMAB + DH... RITUXIMAB + DHA... | 18 Years - | GlaxoSmithKline | |
| EDOCH Alternating With DHAP for New Diagnosed Younger MCL | NCT02858804 | Mantle Cell Lym... | Etoposide Doxorubicin Dexamethasone Vincristine Cyclophosphamid... Cytarabine Cisplatin Rituximab Thalidomide Prednisone | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT01453504 | Hodgkin Lymphom... | DHAP Everolimus | 18 Years - 60 Years | University of Cologne | |
| EDOCH Alternating With DHAP for New Diagnosed Younger MCL | NCT02858804 | Mantle Cell Lym... | Etoposide Doxorubicin Dexamethasone Vincristine Cyclophosphamid... Cytarabine Cisplatin Rituximab Thalidomide Prednisone | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline | |
| Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT01453504 | Hodgkin Lymphom... | DHAP Everolimus | 18 Years - 60 Years | University of Cologne | |
| EDOCH Alternating With DHAP for New Diagnosed Younger MCL | NCT02858804 | Mantle Cell Lym... | Etoposide Doxorubicin Dexamethasone Vincristine Cyclophosphamid... Cytarabine Cisplatin Rituximab Thalidomide Prednisone | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | NCT02280993 | Hodgkin Lymphom... Refractory Relapse | DHAP Brentuximab Ved... Autologous Peri... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
